Detalhe da pesquisa
1.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635381